Vaccines
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
A Phase II study shows the vaccine by Imugene Limited improved survival rates and overall response in patients with HER2-positive stomach or gastroesophageal junction cancer.
The vaccine demonstrated efficacy in mild, moderate, and severe COVID-19 of 77.8% with efficacy against severe disease of 93.4%.
University of Oxford researchers have begun clinical trials for a new vaccine that can potentially target a wide range of HIV variants.
The vaccine, mRNA-1010, targets lineages recommended by the World Health Organization.
The vaccine, dubbed ZyCoV-D, will be the first DNA vaccine available in the world if authorized by regulators.
The company said it would halt activities and focus its resources and time on liver and obesity research following “disappointing” results of its intranasal COVID-19 vaccine.
A new study published in Nature offers good news for those who recovered from COVID-19 and were then vaccinated with a mRNA vaccine – a booster may not be needed.
The groundbreaking success of the mRNA vaccines for COVID-19 by Pfizer-BioNTech and Moderna has led the way for other companies with a vested interest in vaccine development.
The analysis showed that the Pfizer and Oxford/AstraZeneca vaccines can protect patients from being hospitalized by as much as 90 percent.
PRESS RELEASES